Genetic polymorphisms ABCB1 C3435T, CYP3A4*1G and CYP3A5*3 in a group of kidney transplant recipients and the general population
https://doi.org/10.58708/2074-2088.2025-4(36)-43-52
Abstract
The article presents a comparative analysis of the prevalence of genetic variants of two genes of the CYP3A subfamily and gene ABCB1 in a group of kidney transplant recipients and a comparison group in order to determine regional features of the frequencies of clinically significant variants of the genes studied.
Molecular genetic analysis revealed that in a group of 81 kidney transplant recipients and a general population of 92 individuals, the frequency of the clinically significant allele for the 3435C>T polymorphism of the ABCB1 gene was 0,438 and 0,533, respectively; for CYP3A4*1G, it was 0,068 and 0,076; and for CYP3A5*3, it was 0,056 and 0,033, respectively. No significant differences in allele and genotype frequencies were found between the study groups.
The prevalence of allelic variants of the studied genes was comparable to European population values.
About the Authors
А. Е. Silin
ГУ «РНПЦ радиационной медицины и экологии человека»
Belarus
Belarus
S. L. Zyblev
ГУ «РНПЦ радиационной медицины и экологии человека»
Belarus
Belarus
V. N. Martinkov
ГУ «РНПЦ радиационной медицины и экологии человека»
Belarus
Belarus
B. O. Kabeshev
ГУ «РНПЦ радиационной медицины и экологии человека»
Belarus
Belarus
References
1. Калачик, О.В. Донорзависимые факторы риска развития ранней дисфункции аллографта при трупной трансплантации почки / О.В. Калачик // Медицинские новости. – 2018. – № 4 (283). – С. 37–41.
2. Predictors and outcomes of delayed graft function after living-donor kidney transplantation / R.R. Redfield [et al.] // Transplant International. – 2016. – Vol. 29, №1. – P. 81–87.
3. Столяревич, Е. С. Поздняя дисфункция трансплантированной почки: причины, морфологическая характеристика, подходы к профилактике и лечению / Е.С. Столяревич, Н.А. Томилина // Вестник трансплантологии и искусственных органов. – 2009. – Т. 11, №3. – С. 114–122.
4. Cheung, C.Y. Personalized immunosuppression after kidney transplantation / C.Y. Cheung, S.C.W. Tang // Nephrology. – 2022. – Vol. 27, №6. – P. 475–483.
5. The pharmacogenetics of tacrolimus and its implications for personalized therapy in kidney transplant recipients / M.I. Francke [et al.] // Expert Review of Precision Medicine and Drug Development. – 2020. – Vol. 5, №5. – P. 313–316.
6. Персонализированный протокол назначения пролонгированной формы такролимуса реципиентам почечного трансплантата в раннем послеоперационном периоде / А.В. Шабунин [и др.] // Вестник трансплантологии и искусственных органов. – 2023. – Т. 25, №1. – С. 52–61.
7. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing / K.A. Birdwell [et al.] // Clinical Pharmacology and Therapeutics. – 2015. – Vol. 98, №1. – P. 19–24.
8. The impact of IL-10 and CYP3A5 gene polymorphisms on dose-adjusted trough blood tacrolimus concentrations in early postrenal transplant recipients / Z. Chen [et al.] // Pharmacological Reports. – 2021. – Vol. 73, №5. – P. 1418–1426.
9. Barry, A. A Systematic Review of the Effect of CYP3A5 Genotype on the Apparent Oral Clearance of Tacrolimus in Renal Transplant Recipients / A. Barry, M. Levine // Therapeutic Drug Monitoring. – 2010. – Vol. 32, №6. – P. 708–714.
10. Failure of Achieving Tacrolimus Target Blood Concentration Might Be Avoided by a Wide Genotyping of Transplanted Patients: Evidence from a Retrospective Study / G. Pallio [et al.] // Journal of Personalized Medicine. – 2020. – Vol. 10, №2. – P. 47.
11. Перспективы использования полиморфизма C3435T гена Р-гликопротеина ABCB1 в персонализированной медицине / Р.Е. Казаков [и др.] // Ведомости Научного центра экспертизы средств медицинского применения. – 2017. – Т. 7, №4. – С. 212-220.
12. Single-Nucleotide Polymorphism C3435T in the ABCB1 Gene is Associated with Opioid Consumption in Postoperative Pain / K. Candiotti [et al.] // Pain Medicine. – 2013. – Vol. 14. – P. 1977–1984.
13. The Genetic Polymorphisms of CYP3A4*1G and CYP3A5*3 in Javanese Indonesian Population / S.P. Atmaja [et al.] // Journal of Tropical Life Science. – 2024. – Vol. 14, №1. – P. 45-54.
14. Частота полиморфизмов генов CYP2C19 и ABCB1, ассоциированных с изменением антиагрегантного действия клопидогрела, у русских и бурят / Е.Ю. Китаева [и др.] // Сибирское медицинское обозрение. – 2018. – № 3. – С. 43-50.
15. Detection of C1236T, G2677T/A, and C3435T Polymorphism of MDR1 by Amplification Refractory Mutation System PCR / B. Chen [et al.] // Journal of Clinical Laboratory Analysis. – 2009. – № 23. – P. 110–116.
16. Significant impacts of CYP3A4*1G and CYP3A5*3 genetic polymorphisms on the pharmacokinetics of diltiazem and its main metabolites in Chinese adult kidney transplant patients / L.-Y. Zhou [et al.] // Journal of Clinical Pharmacy and Therapeutics. – 2016. – Vol. 41. – P. 341–347.
17. CYP3A4 * 1G Genetic Polymorphism Influences Metabolism of Fentanyl in Human Liver Microsomes in Chinese Patients / J.-J. Yuan [et al.] // Pharmacology. – 2015. – Vol. 96. – P. 55–60.
18. Characterization of CYP3A pharmacogenetic variation in American Indian and Alaska Native communities, targeting CYP3A4*1G allele function / A.E. Fohner [et al.] // Clin Transl Sci. – 2021. – Vol. 14. – P. 1292–1302.
19. Genotype relationships in the CYP3A locus in Caucasians / H. Dally [et al.] // Cancer Letters. – 2004. – Vol. 207. – P. 95–99.
20. Association of CYP3A4 and CYP3A5 polymorphisms with Iranian breast cancer patients / E. Badavi [et al.] // The Egyptian Journal of Medical Human Genetics. – 2015. – Vol. 16. – P. 219–225.
Review
For citations:
Silin А.Е., Zyblev S.L., Martinkov V.N., Kabeshev B.O. Genetic polymorphisms ABCB1 C3435T, CYP3A4*1G and CYP3A5*3 in a group of kidney transplant recipients and the general population. Medical and Biological Problems of Life Activity. 2025;(4):43-52. (In Russ.) https://doi.org/10.58708/2074-2088.2025-4(36)-43-52
Views:
17
Email this article 